{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:49:49Z","timestamp":1793821789406,"version":"4.6.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014361","name":"Hubei University of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bcp.2025.117093","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:19:13Z","timestamp":1751581153000},"page":"117093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Arsenic compounds in cancer therapy: mechanistic insights and antitumor activity"],"prefix":"10.1016","volume":"240","author":[{"given":"Xian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-3114","authenticated-orcid":false,"given":"Dongdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117093_b0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0883-2927(02)00018-5","article-title":"A review of the source, behaviour and distribution of arsenic in natural waters","volume":"17","author":"Smedley","year":"2002","journal-title":"Appl. Geochem."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2025.117093_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.scitotenv.2007.02.037","article-title":"Arsenic in the environment: Biology and Chemistry","volume":"379","author":"Bhattacharya","year":"2007","journal-title":"Sci. Total Environ."},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0015","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/carcin\/bgaa076","article-title":"Metals and molecular carcinogenesis","volume":"41","author":"Zhu","year":"2020","journal-title":"Carcinogenesis"},{"issue":"13","key":"10.1016\/j.bcp.2025.117093_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311031","article-title":"Regulatory Mechanisms Underlying Arsenic Uptake, Transport, and Detoxification in Rice","volume":"24","author":"Geng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"28","key":"10.1016\/j.bcp.2025.117093_b0025","doi-asserted-by":"crossref","first-page":"18583","DOI":"10.1074\/jbc.R900003200","article-title":"Biological responses to arsenic compounds","volume":"284","author":"Platanias","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"Suppl","key":"10.1016\/j.bcp.2025.117093_b0030","first-page":"121","article-title":"Toxicity of arsenic (III) on isolated liver mitochondria: a new mechanistic approach","volume":"12","author":"Hosseini","year":"2013","journal-title":"Iran. J. Pharm. Res.: IJPR"},{"issue":"11","key":"10.1016\/j.bcp.2025.117093_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/nu12113305","article-title":"Arsenic exposure and breast cancer risk: a re-evaluation of the literature","volume":"12","author":"Pullella","year":"2020","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.bcp.2025.117093_b0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1139\/w11-062","article-title":"Role of arsenic and its resistance in nature","volume":"57","author":"Kaur","year":"2011","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.bcp.2025.117093_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104539","article-title":"Arsenic exposure: a public health problem leading to several cancers","volume":"110","author":"Palma-Lara","year":"2020","journal-title":"Regul. Toxicol. Pharmacol.: RTP"},{"key":"10.1016\/j.bcp.2025.117093_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemosphere.2023.137735","article-title":"The relevance of arsenic speciation analysis in health & medicine","volume":"316","author":"Virk","year":"2023","journal-title":"Chemosphere"},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020235","article-title":"Arsenic toxicity: molecular targets and therapeutic agents","volume":"10","author":"Nurchi","year":"2020","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0060","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10557-021-07313-9","article-title":"A clinical perspective on arsenic exposure and development of atherosclerotic cardiovascular disease","volume":"37","author":"Kaur","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0065","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.21037\/tcr.2020.02.17","article-title":"Arsenic trioxide induces gasdermin E mediated pyroptosis in astroglioma cells","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11427-013-4487-z","article-title":"A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered","volume":"56","author":"Rao","year":"2013","journal-title":"Sci. China Life Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0075","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/leu.2011.245","article-title":"Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia","volume":"26","author":"Lengfelder","year":"2012","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.bcp.2025.117093_b0080","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2015-04-636217","article-title":"ATRA and ATO team up against NPM1","volume":"125","author":"Grant","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117093_b0085","article-title":"Toxicity of inorganic arsenic to animals and its treatment strategies","volume":"271","author":"Su","year":"2023","journal-title":"Compar. Biochem. Physiol. Toxicol. Pharmacol.: CBP"},{"key":"10.1016\/j.bcp.2025.117093_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2020.111752","article-title":"Different mechanisms of arsenic related signaling in cellular proliferation, apoptosis and neo-plastic transformation","volume":"208","author":"Medda","year":"2021","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"4\u20135","key":"10.1016\/j.bcp.2025.117093_b0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2010.04.001","article-title":"Arsenic trioxide - an old drug rediscovered","volume":"24","author":"Emadi","year":"2010","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2025.117093_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1245049","article-title":"Role of ROS and RNS sources in physiological and pathological conditions","volume":"2016","author":"Di Meo","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"8","key":"10.1016\/j.bcp.2025.117093_b0105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00204-010-0554-4","article-title":"Influence of arsenate and arsenite on signal transduction pathways: an update","volume":"84","author":"Druwe","year":"2010","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-03357-1","article-title":"Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT\/mTOR pathway","volume":"12","author":"Fang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2025.117093_b0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijpharm.2012.01.024","article-title":"Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for phase I clinical trial","volume":"426","author":"Elliott","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2025.117093_b0120","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.freeradbiomed.2019.11.013","article-title":"The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia","volume":"146","author":"Zhang","year":"2020","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2015.11.004","article-title":"Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia","volume":"30","author":"Torka","year":"2016","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0135","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3324\/haematol.2019.229583","article-title":"Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders","volume":"105","author":"Ravandi","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0140","first-page":"154","article-title":"Safety and efficacy of compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms","volume":"14","author":"Huang","year":"2022","journal-title":"Chin. Herb. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajh.22232","article-title":"A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma","volume":"87","author":"Hosein","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcp.2025.117093_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115908","article-title":"Discovery of novel organoarsenicals as robust thioredoxin reductase inhibitors for oxidative stress mediated cancer therapy","volume":"218","author":"She","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/17474086.2014.903794","article-title":"RARA fusion genes in acute promyelocytic leukemia: a review","volume":"7","author":"De Braekeleer","year":"2014","journal-title":"Expert Rev. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117093_b0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hemonc.2020.05.007","article-title":"Genotypic and phenotypic characteristics of acute promyelocytic leukemia translocation variants","volume":"13","author":"Mannan","year":"2020","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"4","key":"10.1016\/j.bcp.2025.117093_b0165","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood.V82.4.1264.1264","article-title":"Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase\/polymerase chain reaction to predict relapse","volume":"82","author":"Huang","year":"1993","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bcp.2025.117093_b0170","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1101\/gad.14.16.2015","article-title":"PML is induced by oncogenic ras and promotes premature senescence","volume":"14","author":"Ferbeyre","year":"2000","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000661","article-title":"PML nuclear bodies","volume":"2","author":"Lallemand-Breitenbach","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117093_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.02.011","article-title":"Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors","volume":"14","author":"Qu","year":"2024","journal-title":"J. Pharm. Anal."},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0185","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/cbin.11563","article-title":"Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias","volume":"45","author":"Yousefnia","year":"2021","journal-title":"Cell Biol. Int."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccr.2010.06.003","article-title":"PML\/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3","volume":"18","author":"Jeanne","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12185-013-1354-4","article-title":"Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia","volume":"97","author":"Tomita","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"5975","key":"10.1016\/j.bcp.2025.117093_b0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0205","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ncb1717","article-title":"Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway","volume":"10","author":"Lallemand-Breitenbach","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nm.3441","article-title":"Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure","volume":"20","author":"Ablain","year":"2014","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.bcp.2025.117093_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310938","article-title":"ATO increases ROS production and apoptosis of cells by enhancing calpain-mediated degradation of the cancer survival protein TG2","volume":"24","author":"Jambrovics","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117093_b0220","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2147\/OTT.S100513","article-title":"Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives","volume":"10","author":"McCulloch","year":"2017","journal-title":"OncoTargets Therapy"},{"issue":"13","key":"10.1016\/j.bcp.2025.117093_b0225","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2010-01-261040","article-title":"Autophagy contributes to therapy-induced degradation of the PML\/RARA oncoprotein","volume":"116","author":"Isakson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molmed.2011.10.001","article-title":"Curing APL through PML\/RARA degradation by As2O3","volume":"18","author":"Lallemand-Breitenbach","year":"2012","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.bcp.2025.117093_b0235","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: a comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.bcp.2025.117093_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246239","article-title":"LDHA suppression altering metabolism inhibits tumor progress by an organic arsenical","volume":"20","author":"Liu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2025.117093_b0245","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1007\/s00432-022-04333-2","article-title":"A novel organic arsenic derivative MZ2 remodels metabolism and triggers mtROS-mediated apoptosis in acute myeloid leukemia","volume":"149","author":"Chen","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117093_b0250","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mito.2019.04.010","article-title":"Overview of thioredoxin system and targeted therapies for acute leukemia","volume":"47","author":"Xie","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.bcp.2025.117093_b0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: a narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J. Blood Med."},{"key":"10.1016\/j.bcp.2025.117093_b0260","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117093_b0265","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.2147\/IJN.S207298","article-title":"Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL","volume":"14","author":"Wang","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"50","key":"10.1016\/j.bcp.2025.117093_b0270","doi-asserted-by":"crossref","first-page":"21683","DOI":"10.1073\/pnas.1016311108","article-title":"As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia","volume":"107","author":"Mao","year":"2010","journal-title":"PNAS"},{"issue":"13","key":"10.1016\/j.bcp.2025.117093_b0275","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood-2004-04-1433","article-title":"Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein","volume":"104","author":"Yin","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0280","first-page":"6267","article-title":"Arsenic trioxide induces the apoptosis and decreases NF-\u03baB expression in lymphoma cell lines","volume":"16","author":"Zhong","year":"2018","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.bcp.2025.117093_b0285","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3892\/or.2014.3369","article-title":"Arsenic trioxide induces autophagy and antitumor effects in Burkitt's lymphoma Raji cells","volume":"32","author":"Li","year":"2014","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0290","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.leu.2401112","article-title":"The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms","volume":"12","author":"Zhang","year":"1998","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.bcp.2025.117093_b0295","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41388-020-1183-x","article-title":"Stabilization of \u03b2-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma","volume":"39","author":"Lazarian","year":"2020","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0300","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3892\/or.2017.5945","article-title":"The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt\/\u03b2\u2011catenin pathway and DNA methyltransferase-1","volume":"38","author":"Li","year":"2017","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0305","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/bjh.17581","article-title":"Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein","volume":"194","author":"Yue","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0310","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12985-017-0784-7","article-title":"Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells","volume":"14","author":"Yin","year":"2017","journal-title":"Virol. J."},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25094713","article-title":"(2,6-Dimethylphenyl)arsonic acid induces apoptosis through the mitochondrial pathway, downregulates XIAP, and overcomes multidrug resistance to cytostatic drugs in leukemia and lymphoma cells in vitro","volume":"25","author":"Wilke","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092483","article-title":"Lenalidomide in combination with arsenic trioxide: an effective therapy for primary effusion lymphoma","volume":"12","author":"Moodad","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0325","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3960\/jslrt.23005","article-title":"Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"63","author":"Negoro","year":"2023","journal-title":"J. Clin. Exper. Hematopathol.: JCEH"},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0330","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bcp.2025.117093_b0335","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/OTT.S67165","article-title":"Arsenic trioxide-based therapy in relapsed\/refractory multiple myeloma patients: a meta-analysis and systematic review","volume":"7","author":"He","year":"2014","journal-title":"OncoTargets Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0340","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c9mt00308h","article-title":"Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases","volume":"12","author":"Wang","year":"2020","journal-title":"Metall. Integr. Biometal Sci."},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032215","article-title":"Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6","volume":"7","author":"Qu","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcp.2025.117093_b0350","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2141.2004.04941.x","article-title":"Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma","volume":"125","author":"Hussein","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0355","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"19","key":"10.1016\/j.bcp.2025.117093_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910232","article-title":"Molecular targeted therapy and immunotherapy for myelodysplastic syndrome","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0365","article-title":"The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis","volume":"28","author":"Huang","year":"2023","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"10","key":"10.1016\/j.bcp.2025.117093_b0370","first-page":"782","article-title":"[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo]","volume":"44","author":"Lu","year":"2006","journal-title":"Zhonghua Er Ke Za Zhi = Chin. J. Pediatr."},{"issue":"16","key":"10.1016\/j.bcp.2025.117093_b0375","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2005.03.7903","article-title":"Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes","volume":"24","author":"Schiller","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117093_b0380","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jim-2018-000953","article-title":"Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis","volume":"67","author":"Huang","year":"2019","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.bcp.2025.117093_b0385","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2017.10.012","article-title":"Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity","volume":"268","author":"Wu","year":"2017","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0390","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.leukres.2011.12.023","article-title":"A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes","volume":"36","author":"Wei","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2025.117093_b0395","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer (dove Medical Press)"},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0400","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1038\/s41598-021-82551-3","article-title":"Arsenic hexoxide has differential effects on cell proliferation and genome-wide gene expression in human primary mammary epithelial and MCF7 cells","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0405","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3892\/or.2014.3085","article-title":"Arsenic hexoxide enhances TNF-\u03b1-induced anticancer effects by inhibiting NF-\u03baB activity at a safe dose in MCF-7 human breast cancer cells","volume":"31","author":"Kim","year":"2014","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0410","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3892\/etm.2011.224","article-title":"Arsenic trioxide induces the apoptosis of human breast cancer MCF-7 cells through activation of caspase-3 and inhibition of HERG channels","volume":"2","author":"Wang","year":"2011","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0415","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jcb.20102","article-title":"Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells","volume":"93","author":"Chow","year":"2004","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0420","first-page":"366","article-title":"Anticancer efficacies of arsenic disulfide through apoptosis induction, cell cycle arrest, and pro-survival signal inhibition in human breast cancer cells","volume":"8","author":"Zhao","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"10127","key":"10.1016\/j.bcp.2025.117093_b0425","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0430","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0024-3205(02)01622-3","article-title":"Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis","volume":"71","author":"Siu","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2025.117093_b0435","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lfs.2018.05.006","article-title":"Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells","volume":"205","author":"Sadaf","year":"2018","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0440","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41419-019-1676-0","article-title":"Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF\/MCM7 complex","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2025.117093_b0445","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41419-024-06685-8","article-title":"Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0450","first-page":"1468","article-title":"Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide\/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients","volume":"24","author":"Duan","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0455","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00330-023-10097-1","article-title":"Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study","volume":"34","author":"Duan","year":"2024","journal-title":"Eur. Radiol."},{"issue":"10251","key":"10.1016\/j.bcp.2025.117093_b0460","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet (london, England)"},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0465","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1097\/CAD.0000000000001246","article-title":"Arsenic sulfide inhibits the progression of gastric cancer through regulating the circRNA_ASAP2\/Wnt\/\u03b2-catenin pathway","volume":"33","author":"Hu","year":"2022","journal-title":"Anticancer Drugs"},{"issue":"12","key":"10.1016\/j.bcp.2025.117093_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123739","article-title":"Arsenic trioxide suppressed migration and angiogenesis by targeting FOXO3a in gastric cancer cells","volume":"19","author":"Zhang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0475","first-page":"612","article-title":"Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP","volume":"21","author":"Abudoureyimu","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0480","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12885-018-4071-9","article-title":"Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2025.117093_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115404","article-title":"The organic arsenical-derived thioredoxin and glutathione system inhibitor ACZ2 induces apoptosis and autophagy in gastric cancer via ROS-dependent ER stress","volume":"208","author":"Li","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0490","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1631\/jzus.B2200351","article-title":"AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer","volume":"24","author":"Li","year":"2023","journal-title":"J. Zhejiang Univ. Sci. B"},{"issue":"10","key":"10.1016\/j.bcp.2025.117093_b0495","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2174\/1568009622666220629154619","article-title":"Arsenic trioxide restrains lung cancer growth and metastasis by blocking the Calcineurin-NFAT pathway by upregulating DSCR1","volume":"22","author":"Yang","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.bcp.2025.117093_b0500","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s12094-023-03092-x","article-title":"(125)I seed implantation enhances arsenic trioxide-induced apoptosis and anti-angiogenesis in lung cancer xenograft mice","volume":"25","author":"Chen","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"49","key":"10.1016\/j.bcp.2025.117093_b0505","doi-asserted-by":"crossref","first-page":"31189","DOI":"10.1073\/pnas.2017152117","article-title":"Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis","volume":"117","author":"Yi","year":"2020","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0510","doi-asserted-by":"crossref","first-page":"507","DOI":"10.62347\/KFAX9239","article-title":"Arsenic trioxide suppresses lung adenocarcinoma stem cell stemness by inhibiting m6A modification to promote ferroptosis","volume":"14","author":"Jin","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117093_b0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072649","article-title":"Combination of arsenic trioxide and valproic acid efficiently inhibits growth of lung cancer cells via G2\/M-phase arrest and apoptotic cell death","volume":"21","author":"Park","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2025.117093_b0520","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/nm.2473","article-title":"A crucial requirement for Hedgehog signaling in small cell lung cancer","volume":"17","author":"Park","year":"2011","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0525","first-page":"1067","article-title":"Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity","volume":"46","author":"Zheng","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0530","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bph.15713","article-title":"Osteosarcoma mechanobiology and therapeutic targets","volume":"179","author":"Shoaib","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"47","key":"10.1016\/j.bcp.2025.117093_b0535","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi0889","article-title":"Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma","volume":"9","author":"Zhong","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0540","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbrc.2018.01.018","article-title":"Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway","volume":"496","author":"Wu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117093_b0545","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.freeradbiomed.2017.02.015","article-title":"Arsenic sulfide induces apoptosis and autophagy through the activation of ROS\/JNK and suppression of Akt\/mTOR signaling pathways in osteosarcoma","volume":"106","author":"Wang","year":"2017","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0550","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12967-022-03862-1","article-title":"Aa-Z2 triggers ROS-induced apoptosis of osteosarcoma by targeting PDK-1","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2025.117093_b0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.027","article-title":"Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis","volume":"520","author":"Cai","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117093_b0560","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.omto.2019.01.006","article-title":"Skp2 expression is inhibited by arsenic trioxide through the upregulation of miRNA-330-5p in pancreatic cancer cells","volume":"12","author":"Gao","year":"2019","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.bcp.2025.117093_b0565","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.trsl.2022.11.007","article-title":"Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1\/PI3K\/AKT\/mTOR axis","volume":"255","author":"Tian","year":"2023","journal-title":"Transl. Res."},{"issue":"47","key":"10.1016\/j.bcp.2025.117093_b0570","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1038\/s41388-019-0930-3","article-title":"Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer","volume":"38","author":"Xu","year":"2019","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0575","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11092580","article-title":"Heme oxygenase-1 inhibition modulates autophagy and augments arsenic trioxide cytotoxicity in pancreatic cancer cells","volume":"11","author":"Ahmad","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.bcp.2025.117093_b0580","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00775-018-1595-z","article-title":"Low dosage of arsenic trioxide (As(2)O(3)) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis","volume":"23","author":"Luo","year":"2018","journal-title":"J. Biol. Inorg. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2025.117093_b0585","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1349-7006.2009.01340.x","article-title":"Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer","volume":"100","author":"Zhang","year":"2009","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0590","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020586","article-title":"BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells","volume":"6","author":"Yuan","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0595","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1530\/ERC-12-0150","article-title":"Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis","volume":"19","author":"Liu","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0600","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41419-022-05257-y","article-title":"Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer","volume":"13","author":"Tang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0605","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41420-021-00638-2","article-title":"Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors","volume":"7","author":"Xu","year":"2021","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0610","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/me.2008-0235","article-title":"Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic","volume":"23","author":"Rosenblatt","year":"2009","journal-title":"Mol. Endocrinol. (baltimore, Md)"},{"key":"10.1016\/j.bcp.2025.117093_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2021.101684","article-title":"Novel combination therapy of prostate cancer cells with arsenic trioxide and flutamide: an in-vitro study","volume":"74","author":"Mirzaei","year":"2022","journal-title":"Tissue Cell"},{"issue":"8","key":"10.1016\/j.bcp.2025.117093_b0620","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1080\/1120009X.2023.2194183","article-title":"Enzalutamide combination with Arsenic trioxide suppresses the progression of castration-resistant prostate cancer","volume":"35","author":"Yang","year":"2023","journal-title":"J. Chemother. (Florence, Italy)"},{"issue":"9","key":"10.1016\/j.bcp.2025.117093_b0625","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1111\/jcmm.17286","article-title":"Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes","volume":"26","author":"Mirzaei","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031579","article-title":"Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells","volume":"7","author":"Chiu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117093_b0635","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.toxlet.2021.11.012","article-title":"The role of Fas-FasL-FADD signaling pathway in arsenic-mediated neuronal apoptosis in vivo and in vitro","volume":"356","author":"Sun","year":"2022","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0640","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13716","article-title":"Arsenic trioxide induces ferroptosis in neuroblastoma by mediating GPX4 transcriptional inhibition","volume":"17","author":"Su","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2025.117093_b0645","doi-asserted-by":"crossref","first-page":"903","DOI":"10.17219\/acem\/147463","article-title":"Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9","volume":"31","author":"Li","year":"2022","journal-title":"Adv. Clin. Exper. Med."},{"issue":"20","key":"10.1016\/j.bcp.2025.117093_b0650","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2174\/0118715206259952230919173611","article-title":"Arsenic trioxide inhibits activation of hedgehog pathway in human neuroblastoma cell line SK-N-BE(2) independent of itraconazole","volume":"23","author":"Liu","year":"2023","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bcp.2025.117093_b0655","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211041454","article-title":"Improved outcomes with induction chemotherapy combined with arsenic trioxide in stage 4 neuroblastoma: a case series","volume":"20","author":"Li","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0660","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1186\/s12885-024-12884-5","article-title":"Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2025.117093_b0665","first-page":"805","article-title":"Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma","volume":"44","author":"Guo","year":"2006","journal-title":"Zhonghua Wai Ke Za Zhi [Chin. J. Surg.]"},{"issue":"2","key":"10.1016\/j.bcp.2025.117093_b0670","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.canlet.2016.07.007","article-title":"Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs","volume":"381","author":"Meister","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2025.117093_b0675","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","article-title":"Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.117093_b0680","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejphar.2017.12.041","article-title":"Targeting of EGFR increaseanti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform","volume":"820","author":"Mesbahi","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117093_b0685","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nm.4402","article-title":"A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors","volume":"23","author":"Neumann","year":"2017","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117093_b0690","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/03602532.2020.1791173","article-title":"Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts","volume":"52","author":"Maimaitiyiming","year":"2020","journal-title":"Drug Metab. Rev."},{"issue":"31","key":"10.1016\/j.bcp.2025.117093_b0695","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.2174\/1381612828666220818150959","article-title":"The inhibitory effect on tumor cells proliferation induced by arsenic through DNMTs and its downstream molecules: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2025.117093_b0700","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.freeradbiomed.2023.02.020","article-title":"Plasmonic optical fiber biosensor development for point-of-care detection of malondialdehyde as a biomarker of oxidative stress","volume":"199","author":"Bencivenga","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.117093_b0705","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2020.12.011","article-title":"Liquid biopsy of methylation biomarkers in cell-free DNA","volume":"27","author":"Luo","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.bcp.2025.117093_b0710","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.7150\/thno.96027","article-title":"Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development","volume":"14","author":"Xiang","year":"2024","journal-title":"Theranostics"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225003582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T21:05:29Z","timestamp":1755810329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225003582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":142,"alternative-id":["S0006295225003582"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117093","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arsenic compounds in cancer therapy: mechanistic insights and antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117093"}}